Crowley N J, Seigler H F
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Ann Surg. 1990 Aug;212(2):173-7. doi: 10.1097/00000658-199008000-00010.
Analysis of 7104 patients with melanoma seen at Duke University identified 168 who experienced their first recurrence 10 or more years after diagnosis, for an incidence of 2.4%. This included patients with all stages of disease. There was no sex, age, or primary site predominance. The mean disease-free interval for cutaneous melanomas was 14.3 years versus 22.3 years for ocular primary melanomas. The prognosis following relapse was related to the site of recurrence. Survival after local or regional node recurrence was often prolonged; survival after distant metastases was usually limited. Patients with ocular primaries had the highest incidence of distant metastases, and the shortest subsequent survival. An additional 483 patients were identified who survived 10 or more years without evidence of recurrence; of these 651 patients with long disease-free intervals, 25% (168 of 651) developed recurrent disease. This demonstrates that a 10-year disease-free interval cannot be considered a cure, and emphasizes the importance of continued annual follow-up.
对在杜克大学就诊的7104例黑色素瘤患者进行分析,发现有168例在诊断后10年或更长时间首次复发,发病率为2.4%。这包括所有疾病阶段的患者。不存在性别、年龄或原发部位优势。皮肤黑色素瘤的平均无病间期为14.3年,而眼原发性黑色素瘤为22.3年。复发后的预后与复发部位有关。局部或区域淋巴结复发后的生存期通常延长;远处转移后的生存期通常有限。眼原发性患者远处转移的发生率最高,随后的生存期最短。另外还确定了483例存活10年或更长时间且无复发证据的患者;在这651例无病间期长的患者中,25%(651例中的168例)发生了复发性疾病。这表明10年无病间期不能被视为治愈,并强调了持续每年随访的重要性。